Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the […]
In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]
ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]
Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]
Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”
Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. (GMI), joins Rich Bendis for the latest episode of BioTalk. They cover topics from her background in the industry to running a publicly traded company in the BioHealth Capital Region. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the […]
